Invention Grant
- Patent Title: Crenolanib for treating FLT3 mutated proliferative disorders
-
Application No.: US15715274Application Date: 2017-09-26
-
Publication No.: US10213423B2Publication Date: 2019-02-26
- Inventor: Vinay K. Jain
- Applicant: Arog Pharmaceuticals, Inc.
- Applicant Address: US TX Dallas
- Assignee: AROG PHARMACEUTICALS, INC.
- Current Assignee: AROG PHARMACEUTICALS, INC.
- Current Assignee Address: US TX Dallas
- Agency: Chalker Flores, LLP
- Agent Edwin S. Flores; Daniel J. Chalker
- Main IPC: A61K9/00
- IPC: A61K9/00 ; A61K45/06 ; G01N33/574 ; A61K31/4709
Abstract:
The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
Public/Granted literature
- US20180015081A1 Crenolanib for Treating FLT3 Mutated Proliferative Disorders Public/Granted day:2018-01-18
Information query
